PCRX
Price
$24.24
Change
-$0.21 (-0.86%)
Updated
Jun 13 closing price
Capitalization
1.36B
50 days until earnings call
TEVA
Price
$16.99
Change
-$0.72 (-4.07%)
Updated
Jun 13 closing price
Capitalization
15.06B
51 days until earnings call
Interact to see
Advertisement

PCRX vs TEVA

Header iconPCRX vs TEVA Comparison
Open Charts PCRX vs TEVABanner chart's image
Pacira BioSciences
Price$24.24
Change-$0.21 (-0.86%)
Volume$490.35K
Capitalization1.36B
Teva Pharmaceutical Industries
Price$16.99
Change-$0.72 (-4.07%)
Volume$13.36M
Capitalization15.06B
PCRX vs TEVA Comparison Chart
Loading...
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PCRX vs. TEVA commentary
Jun 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PCRX is a Hold and TEVA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 16, 2025
Stock price -- (PCRX: $24.24 vs. TEVA: $16.99)
Brand notoriety: PCRX: Not notable vs. TEVA: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: PCRX: 59% vs. TEVA: 107%
Market capitalization -- PCRX: $1.36B vs. TEVA: $15.06B
PCRX [@Pharmaceuticals: Other] is valued at $1.36B. TEVA’s [@Pharmaceuticals: Other] market capitalization is $15.06B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PCRX’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • PCRX’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than PCRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PCRX’s TA Score shows that 4 TA indicator(s) are bullish while TEVA’s TA Score has 3 bullish TA indicator(s).

  • PCRX’s TA Score: 4 bullish, 4 bearish.
  • TEVA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PCRX is a better buy in the short-term than TEVA.

Price Growth

PCRX (@Pharmaceuticals: Other) experienced а -6.66% price change this week, while TEVA (@Pharmaceuticals: Other) price change was -4.39% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.40%. For the same industry, the average monthly price growth was +14.50%, and the average quarterly price growth was +66.97%.

Reported Earning Dates

PCRX is expected to report earnings on Aug 05, 2025.

TEVA is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-0.40% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($15.1B) has a higher market cap than PCRX($1.36B). PCRX has higher P/E ratio than TEVA: PCRX (32.74) vs TEVA (22.62). PCRX YTD gains are higher at: 28.662 vs. TEVA (-22.913). TEVA has higher annual earnings (EBITDA): 1.56B vs. PCRX (155M). TEVA has more cash in the bank: 3.23B vs. PCRX (279M). PCRX has less debt than TEVA: PCRX (586M) vs TEVA (20.2B). TEVA has higher revenues than PCRX: TEVA (15.8B) vs PCRX (675M).
PCRXTEVAPCRX / TEVA
Capitalization1.36B15.1B9%
EBITDA155M1.56B10%
Gain YTD28.662-22.913-125%
P/E Ratio32.7422.62145%
Revenue675M15.8B4%
Total Cash279M3.23B9%
Total Debt586M20.2B3%
FUNDAMENTALS RATINGS
PCRX vs TEVA: Fundamental Ratings
PCRX
TEVA
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
69
Overvalued
PROFIT vs RISK RATING
1..100
10060
SMR RATING
1..100
9394
PRICE GROWTH RATING
1..100
5254
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PCRX's Valuation (52) in the Pharmaceuticals Other industry is in the same range as TEVA (69) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's Profit vs Risk Rating (60) in the Pharmaceuticals Generic industry is somewhat better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than PCRX’s over the last 12 months.

PCRX's SMR Rating (93) in the Pharmaceuticals Other industry is in the same range as TEVA (94) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

PCRX's Price Growth Rating (52) in the Pharmaceuticals Other industry is in the same range as TEVA (54) in the Pharmaceuticals Generic industry. This means that PCRX’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (12) in the Pharmaceuticals Generic industry is significantly better than the same rating for PCRX (100) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew significantly faster than PCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PCRXTEVA
RSI
ODDS (%)
N/A
Bearish Trend 5 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 3 days ago
71%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bullish Trend 3 days ago
75%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
69%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 3 days ago
68%
Advances
ODDS (%)
Bullish Trend 27 days ago
71%
Bullish Trend 19 days ago
71%
Declines
ODDS (%)
Bearish Trend 5 days ago
78%
Bearish Trend 5 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
76%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
PCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGSCX33.80-0.27
-0.79%
Virtus Duff & Phelps Glb Rl Estt Secs C
VPMAX173.84-1.80
-1.02%
Vanguard PRIMECAP Adm
SPIAX63.09-0.71
-1.11%
Invesco S&P 500 Index A
GSMCX36.37-0.49
-1.33%
Goldman Sachs Mid Cap Value Instl
MSEFX11.92-0.17
-1.41%
iMGP Global Select Instl

PCRX and

Correlation & Price change

A.I.dvisor tells us that PCRX and ELAN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PCRX and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PCRX
1D Price
Change %
PCRX100%
-0.86%
ELAN - PCRX
31%
Poorly correlated
-2.54%
TEVA - PCRX
29%
Poorly correlated
-4.07%
NBIX - PCRX
25%
Poorly correlated
-0.50%
ESPR - PCRX
23%
Poorly correlated
-2.50%
ALKS - PCRX
23%
Poorly correlated
-3.09%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-4.07%
AMRX - TEVA
38%
Loosely correlated
-2.64%
VTRS - TEVA
27%
Poorly correlated
-1.87%
ELAN - TEVA
27%
Poorly correlated
-2.54%
TLRY - TEVA
26%
Poorly correlated
-2.95%
CGC - TEVA
25%
Poorly correlated
-3.27%
More